Health – Page 2 – GREEN SUGR

He’s Now Cancer Free After Stage 4 Pancreatic Cancer

Posted on June 28, 2022July 2, 2022 by dylanramsey

Source: CannabisHealthRadio.com | Author: Cannabis Health Radio | Jun 28, 2022

After being diagnosed with pancreatic cancer in the Fall of 2021, Bob and his wife Tami from the U.S. decided to do everything they could to make him well again. Bob underwent 12 rounds of chemotherapy but he also started taking cannabis oil by suppository, working up to a gram a day. Additionally, he changed his diet and started taking supplements. Bob’s doctor “didn’t know how to explain it” when he got the all clear several weeks ago. No sign of cancer. This is an emotional, good news story that’s worth the time to listen.

Colombia’s turn away from prohibition of cannabis will boost the hemp sector

Posted on June 24, 2022July 2, 2022 by dylanramsey

Source: HempToday.net| Author: Hemp Today | June 24, 2021

In a sharp turn from prohibition-based policy, Colombia will look to advantage small cannabis producers and farming cooperatives, according to a government plan under recently elected President Gustavo Petro.

Petro, a former rebel in the M-19 guerrilla group and a longtime legislator, won Colombia’s presidential election last Sunday, cheering hemp and marijuana interests who hope the new president can execute a plan to transition the country from a narco-state through more constructive policies towards cannabis, coca and poppy.

According to the plan: “The cannabis value chain will receive a special boost, in the hands of producers, linking industry and knowledge, as well as the diversification of uses in the field of medicine, textiles and food, among others.”

The strategy is a fundamental shift in the fight against illegal economies that will position Colombia as a cannabis-producing power through avant-garde policies that take advantage of everything the plant offers, the plan suggests.

Export potential

Envisioning an enhanced framework that favors producer families and co-ops through special permitting privileges and technical support intended to boost farming fortunes while also generating tax revenue for the state, the plan calls for clear regulations, robust research and the promotion of cannabis-based products through cooperation among the state, private sector operators and communities.

“In turn, spaces will be opened in international trade with a variety of (cannabis-) derived products,” according to the 54-page plan, which addresses the broader Colombian economy and society.

Rejecting past policies on drugs rooted in criminalization, the plan notes that “The focus on prohibition in dealing with the global drug problem imposed a war on Colombia around the illegal economies of coca, poppy and cannabis.”

‘War has failed’

“This war has failed and the country needs to move towards a new paradigm that brings together global and Latin American will towards a concerted international agenda based on human rights and the construction of peace, the economic transformation of the productive environments without criminalization of growers, the protection of nature, regulation, the judicial submission of criminal organizations and the approach of consumption as a public health issue,” the plan further observes.

Colombia enacted a law late last year that separated low-THC cannabis from medical marijuana and officially cleared industrial hemp from the country’s drug list. That was followed in February by regulations that set a two-tier system for maximum THC levels, with the limit for grain and fiber crops at 0.3%, while production of flowers, commonly processed for CBD, came under a 1.0% THC barrier.

Potential in CBD

The 1.0% THC limit for hemp flowers should facilitate Colombia’s CBD sector because CBD in hemp plants rises in proportion to THC. A growing number of Latin American and Asian countries are moving to the 1.0% barrier from the generally observed global limit of 0.3%, giving them efficiencies in CBD production.

Colombia also earlier this year put in place international trade regulations for medical marijuana, CBD and other cannabinoids to expand exports.

The Petro government’s development strategy also pledges to move away from over-reliance on fossil fuels, ban aerial spraying of exfoliants such as glyphosate, expand social programs, and more aggressively tax the wealthy.

Cannabis-based colon cancer treatment kill 90% of deadly cells

Posted on March 17, 2022March 17, 2022 by dylanramsey

A new study performed by Cannabotech has demonstrated that the company’s range of Integrative-Colon products may be an effective colon cancer treatment, killing 90% of colon cancer cells in a cell model study.

Source: HealthEuropa.eu | Author: HealthEuropa | Mar 17, 2022

Cannabotech is a biotechnology company pioneering oncological products comprised of cannabis and mushroom extracts. In a recent cell model study, the company has demonstrated that its Integrative-Colon products, which are based on an array of cannabinoids from the cannabis plant and various mushroom extracts, eliminated over 90% of colon cancer cells. The findings offer an exciting prospect for the future of colon cancer treatment.

How did the Integrative Colon products perform?

For their study, the researchers analysed the effectiveness of the Integrative Colon products on a range of colon cancer subtypes, representing different molecular changes that a prevalent in these cancer subtypes. The team compared the composition of the products with the activity of each cannabinoid individually.

The results suggested that the composition of the Integrative Colon products was more effective than each cannabinoid individually, highlighting a strong synergy between the active ingredients. These findings back up claims from Cannabotech that to achieve an effective cannabis colon cancer treatment, it is essential to amalgamate a defined, accurate, and science-based formula that cannot be achieved in any cannabis strain that exists in nature.

Additionally, the study showed the different effects of each cannabinoid on distinct colon cancer subtypes. This echoes the essential need for a individualised approach for patients’ health needs, such as the personalised technology already developed by Cannabotech that will soon hit the market in the UK, US, and Israel at the end of 2022.

The mushroom extracts in the products contain an enriched and high concentration of an active substance called PSK that is extracted from the Trametes mushroom. PSK is known for its anti-cancer properties and has been approved as an oncology treatment in Taiwan, Japan, and South Korea.

Future steps

The researchers are now looking to assess the effectiveness of the formula in combination with standard chemotherapies. In addition, the team plan to combine the cannabinoid formula with the mushroom Cyathus Striatus as part of the botanical drug development project.

Elhanan Shaked, the CEO of Cannabotech, commented: “This is a significant milestone in Cannabotech’s growth to becoming a leader in integrative oncology medicine. The integrative products developed by Cannabotech are intended for use in combination with chemotherapy treatment to reduce its side effects. Cannabotech’s solutions will be launched in Israel and the US towards the second half of 2022, while the company’s goal is to define a new standard for the medical cannabis industry.”

Professor Tami Peretz, Senior Oncologist, said: “Colon cancer is one of the most common tumours today, with a significant proportion of patients currently treated with integrative therapies, in combination with traditional methods, including the administration of medical cannabis. Cannabotech’s Integrative products are unique in that they are designed to standards similar to those of the pharmaceutical industry and incorporate many active ingredients. The company’s products have demonstrated impressive and very promising efficacy in colon culture cells tested in the laboratory. Based on these experiments, there is room to perform animal studies and, in the future, to examine the possibility of incorporating these products in colorectal cancer patients.”

Isaac Angel, Cannabotech’s pharmacological consultant, said: “The significant synergistic effect demonstrated by the combination of active ingredients eliminated over 90% of all types of cancer cells used in the study. Furthermore, this was achieved without the presence of THC, which is the cannabinoid substance producing the “high” effect, whereas each of the other cannabinoids tested individually demonstrated different effects on the various cell types. We are encouraged by these results, which constitute another important milestone in proving the scientific feasibility of the products and highlight the need for medical care customisation. We shall continue to work to provide a cure for patients.”

Olivia Newton-John Relies On Her Husband’s Homegrown Cannabis For Relieving Cancer Symptoms

Posted on March 15, 2022March 15, 2022 by dylanramsey

The Grease actress says cannabis is a “healing plant” and wants nothing more than Aussies to gain legal access to plant-based medicine.

Source: Herb.co | Author: BuzzMusic | Mar 15, 2022

In 1992, actress and singer Olivia Newton-John was first diagnosed with breast cancer but didn’t see any signs of it letting up until entering remission in 2013. Now, reports say the star is under the weight of cancer once again, this time spreading to her spine.

Aside from the unfortunate diagnosis and state of her health, Newton-John focuses on the “positive side of things, no matter what the challenge,” she told The Daily Mail while also citing that cannabis has played a major role in her everyday life.

She first started considering cannabis use when her husband, John Easterling, began cultivating many different strains on their farm in California. A Good Housekeeping article mentioned how Easterling began his ventures in plant-based medicine in the 90s after founding herbal wellness business Amazon Herb Company.

Fast forward to today, Easterling is proud to be growing a handful of different strains, 21 to be exact, that were all specifically designed to combat chronic pain, nausea, and inflammation for Newton-John.

And so far, she’s loved every one of them. In 2020, the Grease actress sat down for an interview with Andy Cohen on Watch What Happens Live, where she explained how cannabis has truly helped her with “pain, with sleep, with anxiety, I believe with inflammation,” reports Prevention.

Prevention also wrote that Newton-John’s positive experience with cannabis resulted in her urging the Australian government to legalize medical marijuana. She added that it’s a “healing plant” and “is something that should be available to everyone who is going through a chronic illness or pain.”

Her admiration for medical marijuana has extended into ventures with her Olivia Newton-John Foundation Fund: Beyond Cancer, which sheds like on the many benefits of plant-based medicine, not to mention her hospital in Australia, the Olivia Newton-John Cancer Wellness, and Research Center.

Study: History of Marijuana Use Not Associated with Increased Heart Attack Risk

Posted on February 21, 2022February 21, 2022 by dylanramsey

Source: Norml.org | Author: Norml | Feb 17, 2022

New York, NY: Cannabis smoke exposure is not positively associated with an increased risk of myocardial infarction, according to data published in the journal Cureus.

A pair of researchers with the Icahn School of Medicine at Mount Sinai in New York City assessed the association between a history of cannabis smoking and heart attack in a cohort of over 500,000 subjects from the United Kingdom.

Researchers identified an inverse association between cannabis use and incidences of myocardial infarction, and they found no correlation between marijuana consumption and heart attack severity.

“With marijuana use, MI [myocardial infarction] decreased,” authors concluded. They further acknowledged: “The association of marijuana use with reduced risk of MI is not entirely in accord with current assumptions about the cardiac effects of marijuana. … Further studies are warranted.”

Studies assessing the association between cannabis use and cardiovascular health have been inconsistent, with some studies finding an increased risk of stroke and other cardiovascular diseases among marijuana consumers while others report either no risk or provide evidence of possible cardioprotection.

Full text of the study, “Marijuana and myocardial infarction in the UK Biobank cohort,” appears in Cureus.

CBD might help prime cells against COVID

Posted on January 15, 2022January 26, 2022 by dylanramsey

CBD in therapeutic amounts seem to increase the innate anti-viral system of cells readiness to respond to viral infection

Source: University of Waterloo | Author: A.J. Herrington | Jan 11, 2022

Synthetic cannabidiol, a non-psychoactive compound also found in the cannabis plant, appears to prime the innate immune system of cells, potentially offering protection against pathogens such as SARS-CoV-2.

Researchers found that synthetic cannabidiol (CBD) augments the anti-viral response of cells to three key proteins produced by the SARS-CoV-2 genome – which was, until now, an unknown effect.

The researchers studied these proteins in human kidney cells, both alone and in combination with CBD, as well as the effects of CBD in healthy control cells.

“When cells in the lungs or the digestive tract are infected with a virus, they have an ability to sense and respond, even before the immune system notices a virus is present,” said Robin Duncan, lead investigator and a professor in the University of Waterloo’s Department of Kinesiology and Health Sciences. “They do this by activating innate responses inside of cells, which form the first line of defence. In the case of COVID-19, however, this response isn’t very good, which has contributed to high infection rates.

“With an RNA-type virus, like SARS-CoV-2, cells should activate an innate system that cuts up the viral genome, which also causes infected cells to undergo a process called apoptosis – a sort of controlled cell death that gets rid of infected cells early on. This could stop an infection, or slow its spread in the body or to others. When we combined CBD with these viral proteins, they had a much better ability to activate this system and to activate apoptosis.”

Duncan said what was potentially even more exciting, however, was that in cells that had not been exposed to the SARS-CoV-2 proteins, CBD in therapeutic amounts seemed to prime the innate anti-viral system of cells, increasing their readiness to respond to viral infection – and that this happened without activating apoptosis in healthy cells.

Waterloo’s postdoctoral fellow Maria Fernandes, who performed the cell studies, said, “This suggests CBD at the right dose could help cells be in a better state of readiness to respond to a virus, but it doesn’t cause a response unless there is a need.”

Duncan said this idea is supported by evidence from users of a high-dose pharmaceutical CBD licensed in the United States for the treatment of rare types of epilepsy. In that study, patients taking prescription high-dose CBD had around a 10-fold lower risk of testing positive for COVID-19.

Duncan points out that CBD does not cause a high, the way THC does, making it more widely useful.

The study, “Effect of cannabidiol on apoptosis and cellular interferon and interferon-stimulated gene responses to the SARS-CoV-2 genes ORF8, ORF10 and M protein,” is co-authored by Duncan, Fernandes, John Zewen Chan, Chia Chun Joey Hung and Michelle Tomczewski. A pre-peer-reviewed version is published on BioRxiv.org, and is under review in the journal Life Sciences.

The researchers said the discovery of this study is not meant to replace practices that are known to work in reducing the spread of COVID-19, such as masking, vaccination and other measures recommended by health experts.

Study Finds Cannabis Compounds Prevent Infection By Covid-19 Virus

Posted on January 11, 2022January 26, 2022 by dylanramsey

Source: Forbes .com | Author: A.J. Herrington | Jan 11, 2022

Compounds in cannabis can prevent infection from the virus that causes Covid-19 by blocking its entry into cells, according to a study published this week by researchers affiliated with Oregon State University. A report on the research, “Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants,” was published online on Monday by the Journal of Natural Products.

The researchers found that two cannabinoid acids commonly found in hemp varietals of cannabis, cannabigerolic acid, or CBGA, and cannabidiolic acid, also known as CBDA, can bind to the spike protein of SARS-CoV-2, the virus that causes Covid-19. By binding to the spike protein, the compounds can prevent the virus from entering cells and causing infection, potentially offering new avenues to prevent and treat the disease.

“Orally bioavailable and with a long history of safe human use, these cannabinoids, isolated or in hemp extracts, have the potential to prevent as well as treat infection by SARS-CoV-2,” the researchers wrote in an abstract of the study.

The study was led by Richard van Breemen, a researcher with Oregon State’s Global Hemp Innovation Center in the College of Pharmacy and Linus Pauling Institute, in collaboration with scientists at the Oregon Health & Science University. Van Breeman said that the cannabinoids studied are common and readily available.

“These cannabinoid acids are abundant in hemp and in many hemp extracts,” van Breemen said, as quoted by local media. “They are not controlled substances like THC, the psychoactive ingredient in marijuana, and have a good safety profile in humans.”

End of article.

Green Sugr contains all cannabinoids and terpenes making it the most effective legal CBD product in the market worldwide.

Brazilian scientists test CBD against COVID-19 long-haul symptoms

Posted on September 16, 2021January 26, 2022 by dylanramsey

Source: HempIndustryDaily.com | Author: Hemp Industry Daily | Sept 16, 2021

Scientists in Brazil are in the third phase of research testing CBD for the treatment of Long Covid, the persistence of COVID-19 symptoms for more than 60 days.

The effects of Long Covid, capable of recurring for months after infection, can include fatigue, headaches, muscle weakness and insomnia.

Because consumers have been using CBD over the counter for relief from a number of issues, the researchers decided to test it against the coronavirus, according to The Rio Times.

The third phase of the trial will recruit 1,000 volunteers.

Nevada first state to allow veterinary CBD treatment

Posted on September 9, 2021January 26, 2022 by dylanramsey

Source: HempIndustryDaily.com | Author: Hemp Industry Daily | Sept 9, 2021

Nevada veterinarians are the first in the nation to win permission to treat animals with cannabinoids, including CBD.

A new law taking effect Oct. 1 clears vets to recommend and administer hemp and cannabidiol products below 0.3% THC without fear of sanction from the state licensing board, the American Veterinary Medical Association reported Thursday in its journal.

CBD is commonly sold through veterinary channels in all states. But veterinarians could be sanctioned for administering it because the products haven’t been approved for animal use by the U.S.Food and Drug Administration.

The ban remains in place despite promising research on CBD to treat epilepsy in dogs. The FDA allows doctors to prescribe CBD to treat human epilepsy, but the cannabinoid remains off-limits for veterinarians.

The sponsor of the Nevada measure, Assemblyman Steve Yeager, told the AVMA that he hopes more states clear paths for veterinary cannabinoid use.

“I certainly hope that other states follow Nevada’s lead and provide reassurances to licensed veterinarians that they can administer CBD or talk about it with patients without fear of facing disciplinary proceedings,” he said.

Market analytics giant NielsenIQ, which tracks sales of hemp-derived CBD, predicts that pet CBD sales will be roughly $300 million this year and about $500 million by 2025.

Clinical Study Reports No Evidence of Liver Toxicity in CBD

Posted on March 24, 2021February 21, 2022 by dylanramsey

Source: Hemp Supporter | Author: Hemp Supporter | Mar 24, 2021

We’re excited to announce the results of an important clinical study conducted by ValidCare on CBD: Preliminary results reveal no evidence of liver toxicity.

Since passage of the 2018 Farm Bill, the FDA has been investigating a pathway to regulate the sale of ingestible hemp-derived CBD products. Unfortunately, the agency has not taken any concrete steps, claiming that it needs more real-world data on CBD’s safety profile.

As part of the hemp industry’s continuing effort to provide FDA data, ValidCare commissioned a study and concluded that “preliminary findings show no evidence of liver disease in the 839 participants and no increase in the prevalence of elevated liver function tests when compared to a population with a similar incidence of medical conditions.”

Major kudos to ValidCare, as well as to the US Hemp Roundtable members who funded and participated in the study: American Shaman, CBD Distillery, Charlotte’s Web, Hemp Fusion, Kannaway and Medterra.

Evidence like this confirms that it is high time for FDA to legally recognize and regulate ingestible hemp-derived CBD products. That’s why it’s so important that Congress pass HR 841, which would establish a legal pathway for the sale of hemp-derived extracts as dietary supplements.

Please use our online portal to email your U.S. Representative today, urging him or her to co-sponsor HR 841.